The New England Journal of Medicine NOVEMBER 13, 2020

The International Polycap Study 3 (TIPS-3)

Salim Yusuf, Prem Pais, et al.

Bottom Line

The TIPS-3 trial demonstrated that a once-daily polypill containing a statin and three antihypertensive agents, particularly when combined with low-dose aspirin, significantly reduces the risk of major adverse cardiovascular events in individuals at intermediate cardiovascular risk.

Key Findings

1. The combination of the polypill plus 75 mg/day of aspirin significantly reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, heart failure, resuscitated cardiac arrest, or arterial revascularization) by 31% compared to a double placebo (hazard ratio 0.69; 95% CI 0.50-0.97).

2. Treatment with the polypill alone resulted in a 21% relative reduction in the primary outcome compared to placebo (hazard ratio 0.79; 95% CI 0.63-1.00), which reached borderline statistical significance.

3. Aspirin monotherapy showed a 14% relative reduction in the composite of cardiovascular death, myocardial infarction, or stroke, though this did not reach statistical significance on its own.

4. A sensitivity analysis excluding participants who discontinued medication for non-medical reasons showed a 39% relative risk reduction with the polypill plus aspirin, suggesting the primary intention-to-treat analysis was likely diluted by non-adherence.

Study Design

Design

RCT

Double-Blind

Sample

5,713

Patients

Duration

4.6 yr

Median

Setting

Multicenter, International

Population Men aged 50 or older and women aged 55 or older at intermediate cardiovascular risk, defined by an INTERHEART risk score of 10 or greater (or 5 or greater if age 65+), without established cardiovascular disease.

Intervention A once-daily polypill containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril, with or without 75 mg of aspirin.

Comparator Matching placebo (and aspirin placebo for the aspirin comparison).

Outcome A composite of death from cardiovascular causes, myocardial infarction, stroke, resuscitated cardiac arrest, heart failure, or arterial revascularization.

Study Limitations

• High rates of treatment discontinuation, reaching 43% by the study's end, significantly impacted the intention-to-treat analysis and likely underestimated the treatment effect.

• The trial was interrupted and impacted by the COVID-19 pandemic, which further exacerbated adherence challenges and distribution delays.

• The observed reductions in blood pressure and LDL cholesterol levels were smaller than anticipated based on the pharmacological components of the polypill, suggesting lower-than-ideal potency or adherence issues.

• The study population was predominantly from South and Southeast Asia, which may limit the generalizability of these findings to other global regions.

Clinical Significance

The TIPS-3 trial supports the potential of a fixed-dose 'polypill' strategy as a cost-effective, simplified approach for population-level cardiovascular primary prevention, particularly in settings where long-term adherence to multi-drug regimens is challenging.

Historical Context

The 'polypill' concept, originally proposed by Wald and Law in 2003, hypothesized that a combined low-dose pill could drastically reduce cardiovascular disease at a population level; TIPS-3 serves as a landmark Phase III validation, building upon earlier pilot studies (TIPS-1 and TIPS-2) and meta-analyses, while addressing long-standing questions regarding the clinical efficacy of this approach in primary prevention.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the combination of a statin and three low-dose antihypertensives in a polypill provide a synergistic reduction in cardiovascular risk compared to high-dose monotherapy focusing on a single risk factor?

Key Response

Atherosclerosis is a multi-factorial process driven by the interplay of dyslipidemia and hemodynamic stress (blood pressure). The polypill strategy addresses multiple pathways simultaneously at lower doses, which can achieve a greater additive risk reduction with a lower side-effect profile than titrating a single medication to its maximum dose.

Resident

In patients with intermediate cardiovascular risk, how does the TIPS-3 trial result reconcile the clinical trade-off between the 'treat-to-target' approach versus the 'fixed-dose' polypill approach for primary prevention?

Key Response

Traditional management involves titrating medications to specific LDL or BP targets. TIPS-3 suggests that a fixed-dose 'polypill' strategy significantly reduces MACE without intensive titration, potentially improving adherence and reducing the clinical inertia often seen in primary prevention settings.

Fellow

The TIPS-3 trial demonstrated a clear benefit for the combination of the polypill and aspirin. Given the recent data from ARRIVE, ASCEND, and ASPREE which showed marginal or no benefit for primary prevention with aspirin, what specific characteristics of the TIPS-3 cohort or trial design explain this divergence in findings?

Key Response

The difference may lie in the intermediate-risk profile (as opposed to low-risk) and the potential synergistic effect of lowering blood pressure and LDL simultaneously, which may sufficiently shift the risk-benefit ratio of aspirin to favor a reduction in ischemic events over the increased risk of major bleeding.

Attending

How should the TIPS-3 findings regarding the polypill strategy influence our teaching of population health versus personalized medicine to medical trainees, particularly in resource-limited settings?

Key Response

The study provides a strong evidence base for a 'population-based' approach where simplicity and adherence are prioritized over the nuance of personalized titration. This is especially practice-changing for global health contexts where frequent follow-up and laboratory monitoring for 'treat-to-target' strategies are impractical.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

TIPS-3 utilized a 2x2x2 factorial design to evaluate the polypill, aspirin, and vitamin D. What are the inherent statistical risks regarding 'interaction effects' in this design, and how might a synergistic interaction between the polypill and aspirin affect the power of the study to detect the independent effect of aspirin?

Key Response

Factorial designs assume that the effects of the interventions are independent. If a synergistic interaction exists (where the polypill enhances the benefit of aspirin), analyzing the 'marginal' effects may lead to biased estimates. A PhD-level critique would look for whether the trial was powered to detect these interactions or if it relied on the assumption of additivity.

Journal Editor

Considering that TIPS-3 was largely conducted in low- and middle-income countries (LMICs), how does the 'usual care' control group in these regions impact the internal validity and the magnitude of the hazard ratio when attempting to publish these results for a global audience in a high-impact journal?

Key Response

A major threat to validity is whether the 'control' group reflects the current standard of care in high-income countries. If the control group in LMICs was under-treated compared to US/European guidelines, the observed relative risk reduction of the polypill might be over-inflated, complicating the generalizability of the findings to systems where background statin and BP medication use is already high.

Guideline Committee

Given the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease recommends against routine aspirin for primary prevention in many groups (Class III or IIb), does the TIPS-3 data warrant a specific 'Polypill+Aspirin' recommendation for intermediate-risk patients, or should the aspirin component still be individualized?

Key Response

The committee must weigh the TIPS-3 evidence (which showed a benefit for the combined arm) against the established bleeding risks of aspirin. Current guidelines (AHA/ACC) emphasize the risk of gastrointestinal bleeding; TIPS-3 might support a Class IIa or IIb recommendation for a polypill-based strategy, but the aspirin component remains controversial unless the patient's ischemic risk clearly outweighs their bleeding risk.

Clinical Landscape

Noteworthy Related Trials

2000

HOPE Trial

n = 9,297 · NEJM

Tested

Ramipril 10mg daily

Population

High-risk patients for cardiovascular events

Comparator

Placebo

Endpoint

Composite of MI, stroke, or cardiovascular death

Key result: Ramipril significantly reduced the rates of death, myocardial infarction, and stroke in high-risk patients.

2003

ASCOT-LLA Trial

n = 10,305 · Lancet

Tested

Atorvastatin 10mg daily

Population

Hypertensive patients with average cholesterol levels

Comparator

Placebo

Endpoint

Nonfatal myocardial infarction and fatal coronary heart disease

Key result: Atorvastatin provided a significant reduction in major cardiovascular events compared to placebo in hypertensive patients.

2016

HOPE-3 Trial

n = 12,705 · NEJM

Tested

Rosuvastatin 10mg or Candesartan 16mg/Hydrochlorothiazide 12.5mg

Population

Intermediate-risk individuals without cardiovascular disease

Comparator

Placebo

Endpoint

Composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke

Key result: Rosuvastatin reduced cardiovascular events in intermediate-risk persons, while the blood-pressure lowering component showed benefit mainly in those with elevated systolic blood pressure.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis